Trial Profile
An exploratory single centre, open label, pilot study investigating the efficacy and safety of OBE2109 200 mg daily for 12 weeks followed by 100 mg daily for 12 weeks in uterine adenomyosis
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 May 2022
Price :
$35
*
At a glance
- Drugs Linzagolix (Primary)
- Indications Adenomyosis; Uterine diseases
- Focus Therapeutic Use
- Sponsors ObsEva
- 20 Oct 2021 Primary endpoint (Change from baseline to week 24 in volume of the uterus with adenomyosis measured by Magnetic Resonance Imaging (MRI).) has been met according to an ObsEva media release
- 20 Oct 2021 According to an ObsEva media release, data from this study were presented at the American Society for Reproductive Medicine (ASRM) 2021 Scientific Congress & Expo.
- 20 Oct 2021 Results published in the ObsEva Media Release